Abstract Number: 4CPS-113

DRUG COST SAVING RESULTING FROM METASTATIC MELANOMA CLINICAL TRIALS

Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM). Madrid, España

OBJECTIVES

Background: The development of checkpoint inhibitors-based immunotherapy has completely changed the therapeutic approach of metastatic melanoma (MM). In parallel, the research activity about this tumor continues at a very high level through a large number of active industry-funded clinical trials.

Objective: To estimate the cost saving in MM therapy attributable to clinical trials (CT) in a university tertiary hospital during the period 2016-2017.

METHODS

✓ Observational, retrospective study that takes into account sponsored CT.
✓ The standard therapy (ST) comparison was chosen for each trial according to the Investigator’s brochure and NCCN (National Comprehensive Cancer Network) Guidelines.
✓ Duration of ST-> equated with the time of permanence of the subject in the trial
✓ Dose of ST -> established according to body surface area or weight at recruitment to trial.
✓ Costs of ST -> estimated using hospital-specific tender price on 1 January of each year. It was considered a maximum reuse of vials.

Limitation: We did not consider the cost of working in aseptic conditions and the cost of administering the drugs.

RESULTS

CT for MM : 14
(> 1 patient treated in our center between 2016-2017)

47 PATIENTS TREATED

ESTIMATED COST SAVING
2016: 809,630 €
2017: 804,349 €
(34,340 €/patient)

<table>
<thead>
<tr>
<th>Standard therapy</th>
<th>Number of CT</th>
<th>Patients treated</th>
<th>Estimated cost saving (€)</th>
<th>Ratio between savings and spendings on MM 2016-2017 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunotherapy (ATC: L01XC)</td>
<td>5</td>
<td>34</td>
<td>1,195,294</td>
<td>99.4</td>
</tr>
<tr>
<td>BRAF/MEK inhibitors (ATC: L01XE)</td>
<td>4</td>
<td>7</td>
<td>417,565</td>
<td>44.2</td>
</tr>
<tr>
<td>Alkylating agents (ATC: L01A)</td>
<td>2</td>
<td>6</td>
<td>1,120</td>
<td>-</td>
</tr>
</tbody>
</table>

CONCLUSIONS

✓ CT using Investigational Medicinal Products provided by the sponsor give a considerable saving for our healthcare system within a context of clinical research and innovation.
✓ This saving remained constant between 2016 and 2017 in our study.